CD19 and chronic myelogenous leukemia, BCR-ABL1 positive: In the comparison between groups, the CLL cohort presented the highest levels of B cells (CD19+), which were increased 5.1- (p < 0.0001), 4.2- (p < 0.0001), and 3.7-fold (p < 0.0001), respectively, in comparison with individuals with CML, MM, and Allo-HSCT.